Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Company Information
About this company
Key people
Dwight H. Egan
Chairman of the Board, President, Chief Executive Officer
Richard Abbott
President
Brian L. Brown
Chief Financial Officer, Company Secretary
Eugene Durenard
Independent Director
Edward L. Murphy
Independent Director
James B. Nelson
Independent Director
Richard S. Serbin
Independent Director
Click to see more
Key facts
- Shares in issue229,257.40
- EPICCODX
- ISINUS1897632048
- LocationUnited States
- SectorHealthcare
- IndustryMedical Equipment & Supplies
- Market cap$5.34m
- Employees132
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.